09
May

Merck KGaA has long said it’s not affraid to spend big on bolstering its pipeline, and part of the German drugmaker’s value-creation plan is a sizable investment in biosimilars.

…read more

Source: Merck KGaA bets on biosimilars with an eye on M&A

    

0 No comments